$ANI Pharmaceuticals (ANIP.US)$Revenue has continued to grow...
$ANI Pharmaceuticals(ANIP.US$Revenue has continued to grow in the past 5 years. In particular, it surged by 46.4% in 2022, but operating profit continued to decline. Entering a loss range in 2020, losses intensified in 2021, losses narrowed by 8.6% in 2022, and net profit losses continued to expand since 2020.
2023Q1 revenue surged 65.6%, and both operating profit and net profit reversed losses. Judging from quarterly reports, quarterly revenue and profit continued to grow month-on-month in the past 5 months, which is a good sign of reversing losses.
Currently, there is only one month of profit data, so you can wait a few more quarterly reports before making a judgment.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
